Cantargia Publishes Interim Report for the First Quarter of 2025

About this update from Cantargia Ab

[{"type":"text","content":"LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025.","length":190,"tagName":"p"},{"type":"text","content":""The first quarter of 2025 has been rich in positive news for Cantargia. We continue to progress on all fronts, with strong news flow on all our projects and ongoing discussions regarding potential transactions that can be transformative for Cantargia. However, this has unfortunately been against a backdrop of macroeconomic turmoil and uncertainty which has weighed very heavily on biotech stock markets globally during the period", said Damian Marron, interim CEO of Cantargia.","length":490,"tagName":"p"},{"type":"text","content":"Significant events in the first quarter","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Damian Marron was appointed as interim CEO, following Göran Forsberg's resignation.","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Cantargia presented promising phase 1 results from CAN10's first multiple-dose cohort, as well as feedback from the FDA and clinical experts.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"The randomized phase 2 TRIFOUR study in triple-negative breast cancer was fully recruited.","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"The first patient was enrolled in Cantargia's leukemia study with nadunolimab.","length":82,"tagName":"p"}]},{"val":[{"type":"text","content":"Two abstracts on IL1RAP-ADC and nadunolimab's potential role in reducing chemotherapy induced neuropathy respectively will be presented at the AACR 2025 conference.","length":168,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":572,"olType":false},{"type":"text","content":"Significant events after the end of the period","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cantargia appointed Morten Lind Jensen as Chief Medical Officer.","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Treatment resistant atopic dermatitis (AD) was selected as second indication for CAN10's phase 2 program.","length":109,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharmacokinetic modelling using data from the single ascend...

More updates from Cantargia Ab